Evidence map›Paper›PMID 21747385›Full record

ArticleNature biotechnology2011

Streamlining biomarker discovery.

Martin Latterich, Jan E Schnitzer

Abstract readNewsComment
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. New astroglial injury-defined biomarkers for neurotrauma assessment.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2017
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Martin Latterich
Jan E Schnitzer

Funding

Mapping Vascular Proteome for Organ Targeting in VivoR01HL074063 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TALAMINI, MARK A · 2005 to 2009
$3.8M
Nanotechnology Platform for Targeting Solid TumorsR01CA119378 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TALAMINI, MARK A · 2005 to 2009
$3.6M
TISSUE TARGETING TO ENDOTHELIUM AND ITS CAVEOLAER01HL058216 · NHLBI · SIDNEY KIMMEL CANCER CENTER · PI SCHNITZER, JAN EUGENIUSZ · 1998 to 2006
$2.8M
Targeting Caveolae in Breast TumorsR01CA083989 · NCI · SIDNEY KIMMEL CANCER CENTER · PI SCHNITZER, JAN EUGENIUSZ · 2002 to 2006
$2.2M
Role and Utility of Annexins in Endothelium of Solid TumR01CA115215 · NCI · SIDNEY KIMMEL CANCER CENTER · PI SCHNITZER, JAN EUGENIUSZ · 2004 to 2008
$2.1M
NCI NIH HHS R01 CA083989NCI NIH HHS R01 CA115215NCI NIH HHS R01 CA119378NHLBI NIH HHS R01 HL058216NHLBI NIH HHS R01 HL074063
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsBiomarkersBiomarkers, TumorBlood Chemical AnalysisHumansMass SpectrometryMyocardial InfarctionNeoplasm ProteinsNeoplasms, ExperimentalPeptide MappingProteomeBiomarkersBiomarkers, TumorNeoplasm ProteinsProteome

Identifiers

PMID21747385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.